CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
(Thomson Reuters ONE) -
SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a
wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and
a global drug discovery and development services company providing translational
platforms to advance oncology, inflammation, cardiovascular and metabolic
disease research, announces the availability of their proprietary FATZO(TM)
model in a European based laboratory. The establishment of this improved
translational model provides the European scientific community with unfettered
access to an advanced research tool for use in preclinical studies of obesity,
dysmetabolism and type 2 diabetes.
The FATZO(TM) is a next generation preclinical research model for obesity,
metabolic disorders, diabetes and related complications. The unique feature of
an intact leptin system enables the FATZO model to provide novel scientific
insights into the physiological and cellular mechanisms that lead from obesity /
metabolic disorders to diabetes. It examines polygenic causes of obesity and
mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia
and hyperinsulinemia.
"Obesity and diabetes have a significant global impact, affecting more than 422
million people worldwide. We expanded our FATZO(TM) model to ensure European
researchers have ready access to the best translational tools available to
advance the drug development programs aimed at curing these diseases," said Jim
Wang, M.D., Crown Bioscience's Senior Vice President Cardiovascular and
Metabolic Diseases (CVMD) Research.
"The establishment of our FATZO(TM) model in Europe is pivotal to Crown
Bioscience's commitment to providing translational models that are
representative of human conditions of obesity, type 2 diabetes and related
comorbidities," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. "We look
forward to working with European scientists to help answer their most
challenging questions about these diseases and enable more effective drug
discovery for their treatment."
For more information on CrownBio's commitment to advance the field of
cardiovascular and metabolic drug discovery,
visit https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company
providing translational platforms to advance oncology, inflammation and
metabolic disease research. With an extensive portfolio of relevant models and
predictive tools, Crown Bioscience enables clients to deliver superior clinical
candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing(at)crownbio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via GlobeNewswire
Datum: 10.10.2017 - 15:45 Uhr
Sprache: Deutsch
News-ID 563102
Anzahl Zeichen: 3334
contact information:
Town:
Santa Clara
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 269 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes"
steht unter der journalistisch-redaktionellen Verantwortung von
Crown Bioscience Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
